Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

BTIG analysts upheld their Buy rating and $15.00 price target for Coya Therapeutics (NASDAQ:COYA), following recent clinical trial data. The stock, currently trading at $7.11, has shown strong ...

Findings indicate that altering glucose metabolism in T cells boosts their therapeutic potential against melanoma, paving the way for improved immunotherapies.

A recent study carried out by a research team from the Paul-Ehrlich-Institut investigated the immunomodulating properties of ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

In disease, high levels of IL-1 in the brain are linked to neuroinflammation, which can disrupt the body's stress response, cause sickness-like behaviors, worsen inflammation by activating brain ...

Mechanistically, IL-1β activates RhoA/ROCK signaling through a non-canonical IL-1 receptor-dependent pathway, which drives the enrichment of actin bundles at the cell-cell junctions, thus prevents ...

The other has to do with reducing inflammation. He said there’s also appears to be an effect in the brain, which has GLP-1 receptors, and in the lining of the blood vessels. Some of the most ...

Fortunately, large scale randomised trials with GLP-1RA-based therapies that yield greater weight loss are ongoing and several will report out in the next 1-4 years ... have not been randomly ...

Study of 2.4 million participants reveals potential advantages for cardiometabolic and psychiatric conditions alongside increased risks of gastrointestinal and musculoskeletal issues Study ...